in Newswire September 17, 2019

Sanofi, Boehringer Ingelheim Hit with Class Action Over Allegedly Unsafe Levels of Probable Carcinogen NDMA in Zantac

by Corrado Rizzi

Last Updated on September 17, 2019

Garza et al. v. Sanofi-Aventis U.S. LLC et al.

Filed: September 13, 2019 § 5:19-cv-05772

Zantac makers Sanofi-Aventis U.S. and Boehringer Ingelheim face a class action over the allegedly high NDMA content in the over-the-counter heartburn and indigestion drug.

Last Updated on September 17, 2019 — 11:09 AM

Corrado Rizzi

Corrado Rizzi is the Managing Editor and a writer for

About is a group of online professionals (designers, developers and writers) with years of experience in the legal industry.

Learn More

Before commenting, please review our comment policy.